Startseite › Urothelkarzinom (Transitional Cell Carcinoma) › Tennessee › Nashville
Klinische Studien zu Urothelkarzinom (Transitional Cell Carcinoma) in Nashville, TN
23 Studien zu Urothelkarzinom (Transitional Cell Carcinoma) suchen Teilnehmer an Standorten in und um Nashville (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1
- Tennessee Oncology, Nashville
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Teilnehmer gesuchtPhase 1
- Exelixis Clinical Site #3, Nashville
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Teilnehmer gesuchtPhase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Teilnehmer gesuchtPhase 3
- SCRI Oncology Partners, Nashville
DBC-664 in Adult Patients With Solid Tumors
Teilnehmer gesuchtPhase 1
- SCRI Oncology Partners, Nashville
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Teilnehmer gesuchtBeobachtungsstudie
- Vanderbilt University Medical Center, Nashville
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Teilnehmer gesuchtPhase 1/2
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology, Nashville
- und 9 weitere
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- Sarah Cannon Research Institute, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Teilnehmer gesuchtPhase 1/2
- Vanderbilt University Medical Center, Nashville
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Teilnehmer gesuchtPhase 3
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
Teilnehmer gesuchtPhase 2/3
- Research Site, Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Teilnehmer gesuchtPhase 1
- Sarah Cannon Research Institute, Nashville
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Tennessee Oncology, Nashville
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Teilnehmer gesuchtPhase 2/3
- Research Site, Nashville
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Teilnehmer gesuchtPhase 1
- Vanderbilt- Ingram Cancer Center, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Teilnehmer gesuchtPhase 1/2
- SCRI Oncology Partners, Nashville
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Teilnehmer gesuchtPhase 3
- Research Site, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Teilnehmer gesuchtPhase 2
- SCRI Oncology Partners, Nashville
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Teilnehmer gesucht
- Vanderbilt University Medical Center, Nashville
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Teilnehmer gesuchtPhase 2
- Site 02-007 - Urology Associates, P. C, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Teilnehmer gesuchtBeobachtungsstudie
- Massive Bio SYNERGY-AI site, Nashville
Urothelkarzinom (Transitional Cell Carcinoma)-Studien in anderen Städten
- New York City, NY22 Studien
- Houston, TX19 Studien
- Dallas, TX18 Studien
- Edison, NJ18 Studien
- Los Angeles, CA17 Studien
- Queens, NY15 Studien
- Chicago, IL14 Studien
- Arlington, VA12 Studien
- Boston, MA11 Studien
- San Antonio, TX11 Studien
- Austin, TX10 Studien
- Orange, CA10 Studien
Weitere Studien in Nashville
- Nichtkleinzelliges Lungenkarzinom97 Studien
- Brustkrebs81 Studien
- Metastasierender Krebs70 Studien
- Kolorektales Karzinom69 Studien
- Krebs (alle Arten)65 Studien
- Eierstockkrebs49 Studien
- Prostatakrebs43 Studien
- Lungenkrebs40 Studien
- Plattenepithelkarzinom im Kopf-Hals-Bereich39 Studien
- Bauchspeicheldrüsenkrebs39 Studien
- Endometriumkarzinom38 Studien
- Melanom33 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 06.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.